Review

antibodies against p epha4 tyr 602 (ECM Biosciences)

ECM Biosciences is a verified supplier

ECM Biosciences manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ECM Biosciences antibodies against p epha4 tyr 602
Antibodies Against P Epha4 Tyr 602, supplied by ECM Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p+epha4/pm37741263-113-17-21?v=ECM+Biosciences
Average 93 stars, based on 16 article reviews

antibodies against p epha4 tyr 602 - by Bioz Stars, 2026-08

93/100 stars

Images

Image Search Results

Journal: JCI insight

Article Title: Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment.

doi: 10.1172/jci.insight.166306

Figure Lengend Snippet: Figure 6. Amelioration of CRCI by hippocampal PTPRO is associated with inactivation of the SRC/EPHA4 axis. (A) Representative IHC images of PTPRO, p-SRC, SRC, p-EPHA4, EPHA4, p-EPHB2, and EPHB2 in the hippocampi. Scale bar: 50 μm. (B) The mean optical density of p-SRC/SRC, p-EPHA4/EPHA4, and p-EPHB2/EPHB2 in the hippocampi. (C) Immunoblotting of PTPRO, p-SRC, SRC, p-EPHA4, EPHA4, p-EPHB2, and EPHB2 in the hippocampi under CRCI. Data are representative of 3 independent experiments. (D) The mean optical density of p-SRC/SRC, p-EPHA4/EPHA4, and p-EPHB2/EPHB2 in the hippocampi. Error bars: SEM. NS, not significant; *P < 0.05, ***P < 0.001 by 2-sided Student’s t test.

Article Snippet: The membranes were immersed in blocking buffer (5% skim milk in PBS) for 1 hour at room temperature and incubated 1 9 R E S E A R C H A R T I C L E JCI Insight 2023;8(14):e166306 https://doi.org/10.1172/jci.insight.166306 overnight with primary antibodies used against the following proteins: PTPRO (1:1000; catalog 12161-1- AP, Proteintech Group), p-SRC (1:1000; catalog 2101, Cell Signaling Technology), SRC (1:1000; catalog sc-8056, Santa Cruz Biotechnology), p-EPHB2 (1:1000; catalog ab61791, Abcam), EPHB2 (1:1000; catalog 83029, Cell Signaling Technology), p-EPHA4 (1:1000; catalog EP2731, ECM Biosciences), EPHA4 (1:1000; catalog sc-365503, Santa Cruz Biotechnology), PSD95 (1:1000; catalog 3450, Cell Signaling Technology), Syp (1:1000; catalog ab32127, Abcam), β-actin (1:1000; catalog 4967, Cell Signaling Technology), and GAPDH (1:1000; catalog ab8245, Abcam).

Techniques: Western Blot

Figure 7. Region-specific restoration of hippocampal PTPRO ameliorates DOX-induced CRCI in Ptpro–/– female mice. (A) Schematic of the experimental design. (B) Representative immunofluorescence image of FLAG (green) in the hippocampi of Ptpro–/– mice 2 weeks after injection of Lentivirus-hSyn-Pt- pro-3×Flag into the CA3 region. Scale bar: 200 μm. DG, dentate gyrus. (C) Changes in spontaneous alternation behavior in the Y-maze test. (D) Represen- tative swimming traces in the MWM test. (E and F) Training trials were performed in the MWM test, in which the time taken to reach the submerged plat- form (E) and the distances traveled before reaching the submerged platform (F) were assesssed, n = 10 per group. (G and H) A probe trial was performed in the MWM test. Shown are the time spent in the target quadrant (G) and the number of crossings before reaching the target location (H), n = 10 per group. (I) Immunoblotting of PTPRO, p-SRC, SRC, p-EPHA4, and EPHA4 in the mouse hippocampal CA3 region. Data are representative of 3 independent exper- iments. Error bars: SEM. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001 by 2-way ANOVA followed by a Tukey-Kramer post hoc test (C, G, and H). *Ptpro+/+-LVCon vs. Ptpro–/–-LVCon; #Ptpro–/–-LVCon vs. Ptpro–/–-LVPtpro; *P < 0.05, ***P < 0.001; #P < 0.05 by 3-way ANOVA followed by a Tukey-Kramer post hoc test (E and F). All values and statistical analysis of behavioral experiments are provided in Supplemental Table 4.

Journal: JCI insight

Article Title: Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment.

doi: 10.1172/jci.insight.166306

Figure Lengend Snippet: Figure 7. Region-specific restoration of hippocampal PTPRO ameliorates DOX-induced CRCI in Ptpro–/– female mice. (A) Schematic of the experimental design. (B) Representative immunofluorescence image of FLAG (green) in the hippocampi of Ptpro–/– mice 2 weeks after injection of Lentivirus-hSyn-Pt- pro-3×Flag into the CA3 region. Scale bar: 200 μm. DG, dentate gyrus. (C) Changes in spontaneous alternation behavior in the Y-maze test. (D) Represen- tative swimming traces in the MWM test. (E and F) Training trials were performed in the MWM test, in which the time taken to reach the submerged plat- form (E) and the distances traveled before reaching the submerged platform (F) were assesssed, n = 10 per group. (G and H) A probe trial was performed in the MWM test. Shown are the time spent in the target quadrant (G) and the number of crossings before reaching the target location (H), n = 10 per group. (I) Immunoblotting of PTPRO, p-SRC, SRC, p-EPHA4, and EPHA4 in the mouse hippocampal CA3 region. Data are representative of 3 independent exper- iments. Error bars: SEM. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001 by 2-way ANOVA followed by a Tukey-Kramer post hoc test (C, G, and H). *Ptpro+/+-LVCon vs. Ptpro–/–-LVCon; #Ptpro–/–-LVCon vs. Ptpro–/–-LVPtpro; *P < 0.05, ***P < 0.001; #P < 0.05 by 3-way ANOVA followed by a Tukey-Kramer post hoc test (E and F). All values and statistical analysis of behavioral experiments are provided in Supplemental Table 4.

Techniques: Immunofluorescence, Injection, Western Blot

SORLA interacts with EphA4 and suppresses EphA4 activation in response to ligand stimulation. (A) SORLA coimmunoprecipitates with EphA4. EphA4 or APP was immunoprecipitated with the indicated antibodies and immunoblotted for SORLA, EphA4, or APP. (B) SORLA/EphA4 complexes can be reconstituted by exogenous expression. EphA4 was coexpressed with GST or SORLA-GST in HEK293T or HEKswAPP cell lines, and glutathione Sepharose precipitates were immunoblotted for EphA4, APP (left), or GST (right). A single representative experiment is shown in A and B. (C–E) SORLA overexpression attenuates EphA4 activation. (C) HEK293 cells stably expressing EphA4 were transfected with control or SORLA constructs and incubated with ephrinA1-Fc (A1-Fc) for the time indicated. EphA4 immunoprecipitates were immunoblotted for pY602 phosphorylation or total EphA4. Data in D represents mean ± SE from five independent experiments (*, P < 0.05; Student’s t test). (E) WT or SORLA-overexpressing transgenic (SORLA TG) cortical neurons were stimulated with ephrinA1-Fc, and control or EphA4 immunoprecipitates were immunoblotted for EphA4 pY602 or total EphA4 as indicated. Lysate inputs are shown (right). (F) Cumulative data from E; graphs represent mean ± SE from seven independent experiments (*, P < 0.05; Student’s t test).

Journal: The Journal of Experimental Medicine

Article Title: SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration

doi: 10.1084/jem.20171413

Figure Lengend Snippet: SORLA interacts with EphA4 and suppresses EphA4 activation in response to ligand stimulation. (A) SORLA coimmunoprecipitates with EphA4. EphA4 or APP was immunoprecipitated with the indicated antibodies and immunoblotted for SORLA, EphA4, or APP. (B) SORLA/EphA4 complexes can be reconstituted by exogenous expression. EphA4 was coexpressed with GST or SORLA-GST in HEK293T or HEKswAPP cell lines, and glutathione Sepharose precipitates were immunoblotted for EphA4, APP (left), or GST (right). A single representative experiment is shown in A and B. (C–E) SORLA overexpression attenuates EphA4 activation. (C) HEK293 cells stably expressing EphA4 were transfected with control or SORLA constructs and incubated with ephrinA1-Fc (A1-Fc) for the time indicated. EphA4 immunoprecipitates were immunoblotted for pY602 phosphorylation or total EphA4. Data in D represents mean ± SE from five independent experiments (*, P < 0.05; Student’s t test). (E) WT or SORLA-overexpressing transgenic (SORLA TG) cortical neurons were stimulated with ephrinA1-Fc, and control or EphA4 immunoprecipitates were immunoblotted for EphA4 pY602 or total EphA4 as indicated. Lysate inputs are shown (right). (F) Cumulative data from E; graphs represent mean ± SE from seven independent experiments (*, P < 0.05; Student’s t test).

Article Snippet: Antibodies were all purchased from commercial sources: SORLA (LR11; BD Biosciences), EphA4 (S-20), EphB2 and GST polyclonal (Santa Cruz), FLAG M2 (Stratagene/Sigma), β-actin, βIII-tubulin (Tuj1) and α-tubulin (Sigma), EphA4 monoclonal (Life Technologies/Thermo Fisher Scientific), p-Y602 EphA4 (ECM Biosciences), EphB1 (5F10 mouse monoclonal) and pTyr100 (Cell Signaling Technology).

Techniques: Activation Assay, Immunoprecipitation, Expressing, Over Expression, Stable Transfection, Transfection, Control, Construct, Incubation, Phospho-proteomics, Transgenic Assay

SORLA overexpression attenuates ephrinA1-induced EphA4 clustering. (A) WT hippocampal neurons at DIV3, untreated or exposed to control Fc for 30 min or ephrinA1-Fc for the indicated time, were fixed and stained for EphA4 (green), F-actin (red), or tubulin (blue). Note that ephrinA1-Fc treatment for 5 min results in EphA4 clustering without growth cone collapse. Bar, 5 µm. (B–D) Evaluation of EphA4 clustering in WT, SORLA TG, and KO hippocampal neurons. (B) WT, SORLA TG, and KO hippocampal neurons were treated with ephrinA1-Fc for 5 min and stained for EphA4 (green) and tubulin (blue). Boxed regions are magnified in the adjacent panels. Bar, 10 µm. (C) EphA4 clustering within F-actin–rich areas was examined by microscopy in WT, SORLA TG, and SORLA KO hippocampal neurons at DIV3 by staining for EphA4 (green), F-actin (red), and tubulin (blue). Bar, 5 µm. EphA4 clusters ≥200 nm within F-actin–enriched growth cone regions were scored in a minimum of four independent dissections/experiments (D); graph represents mean ± SE, from individual experiments; *, P < 0.05; **, P < 0.003; Student’s t test. (E) Total EphA4 fluorescence intensities from individual growth cones scored in D were plotted; graph represents mean ± SE.

Journal: The Journal of Experimental Medicine

Article Title: SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration

doi: 10.1084/jem.20171413

Figure Lengend Snippet: SORLA overexpression attenuates ephrinA1-induced EphA4 clustering. (A) WT hippocampal neurons at DIV3, untreated or exposed to control Fc for 30 min or ephrinA1-Fc for the indicated time, were fixed and stained for EphA4 (green), F-actin (red), or tubulin (blue). Note that ephrinA1-Fc treatment for 5 min results in EphA4 clustering without growth cone collapse. Bar, 5 µm. (B–D) Evaluation of EphA4 clustering in WT, SORLA TG, and KO hippocampal neurons. (B) WT, SORLA TG, and KO hippocampal neurons were treated with ephrinA1-Fc for 5 min and stained for EphA4 (green) and tubulin (blue). Boxed regions are magnified in the adjacent panels. Bar, 10 µm. (C) EphA4 clustering within F-actin–rich areas was examined by microscopy in WT, SORLA TG, and SORLA KO hippocampal neurons at DIV3 by staining for EphA4 (green), F-actin (red), and tubulin (blue). Bar, 5 µm. EphA4 clusters ≥200 nm within F-actin–enriched growth cone regions were scored in a minimum of four independent dissections/experiments (D); graph represents mean ± SE, from individual experiments; *, P < 0.05; **, P < 0.003; Student’s t test. (E) Total EphA4 fluorescence intensities from individual growth cones scored in D were plotted; graph represents mean ± SE.

Techniques: Over Expression, Control, Staining, Microscopy, Fluorescence

EphA4 interacts with the SORLA YWTD/EGF-like domain, and EphA4/SORLA interaction is attenuated by a T947M AD-associated SORLA mutation. (A) Schematic diagram of SORLA domains; an AD-associated T947M mutation resides within the YWTD/EGF-like region. (B) The SORLA YWTD/EGF-like region interacts with EphA4. Purified EphA4-FLAGhis6 was incubated with various SORLA domain-Fc fusion proteins immobilized on protein G Sepharose, and coprecipitation with EphA4 was evaluated by immunoblotting. Adjacent graph depicts relative EphA4 coprecipitation (YWTD/EGF set to 1.0). Results are from three independent experiments; graph represents mean ± SE. (C) Purified EphA4 was evaluated for coprecipitation with WT or a T947M variant of the SORLA YWTD/EGF domain fused to Fc as in B. The adjacent graph depicts relative EphA4 binding with the WT construct set to 1.0 in four replicates from two independent experiments, mean ± SE; **, P < 0.005; Student’s t test. (D and E) The SORLA T947M mutation attenuates SORLA/EphA4 interaction and effects on EphA4 activation. HEK293 cells stably expressing EphA4 were transfected with control, WT, or T947M SORLA expression constructs, and EphA4 immunoprecipitates from lysates were evaluated for SORLA coprecipitation (D) or ephrinA1-Fc induced EphA4 activation (E) by immunoblotting. Graphs in D depict T947M coprecipitation relative to WT (set to 1.0; mean ± SE; **, P < 0.005; Student’s t test) from six replicates in four independent experiments. Graphs in E show relative pY602/EphA4 ratios with control vector treatments set to 1.0 (mean ± SE from five replicates in three independent experiments; *, P < 0.015; paired Student’s t test).

Journal: The Journal of Experimental Medicine

Article Title: SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration

doi: 10.1084/jem.20171413

Figure Lengend Snippet: EphA4 interacts with the SORLA YWTD/EGF-like domain, and EphA4/SORLA interaction is attenuated by a T947M AD-associated SORLA mutation. (A) Schematic diagram of SORLA domains; an AD-associated T947M mutation resides within the YWTD/EGF-like region. (B) The SORLA YWTD/EGF-like region interacts with EphA4. Purified EphA4-FLAGhis6 was incubated with various SORLA domain-Fc fusion proteins immobilized on protein G Sepharose, and coprecipitation with EphA4 was evaluated by immunoblotting. Adjacent graph depicts relative EphA4 coprecipitation (YWTD/EGF set to 1.0). Results are from three independent experiments; graph represents mean ± SE. (C) Purified EphA4 was evaluated for coprecipitation with WT or a T947M variant of the SORLA YWTD/EGF domain fused to Fc as in B. The adjacent graph depicts relative EphA4 binding with the WT construct set to 1.0 in four replicates from two independent experiments, mean ± SE; **, P < 0.005; Student’s t test. (D and E) The SORLA T947M mutation attenuates SORLA/EphA4 interaction and effects on EphA4 activation. HEK293 cells stably expressing EphA4 were transfected with control, WT, or T947M SORLA expression constructs, and EphA4 immunoprecipitates from lysates were evaluated for SORLA coprecipitation (D) or ephrinA1-Fc induced EphA4 activation (E) by immunoblotting. Graphs in D depict T947M coprecipitation relative to WT (set to 1.0; mean ± SE; **, P < 0.005; Student’s t test) from six replicates in four independent experiments. Graphs in E show relative pY602/EphA4 ratios with control vector treatments set to 1.0 (mean ± SE from five replicates in three independent experiments; *, P < 0.015; paired Student’s t test).

Techniques: Mutagenesis, Purification, Incubation, Western Blot, Variant Assay, Binding Assay, Construct, Activation Assay, Stable Transfection, Expressing, Transfection, Control, Plasmid Preparation

$SORLA suppresses Aβ-mediated EphA4 activation and attenuates cognitive and synaptotoxic deficits associated with oligomeric Aβ injection in SORLA TG mice. (A and B) SORLA TG mice show a slight reduction in EphA4 activation at steady state. (A) EphA4 immunoprecipitates from crude synaptosome fractions in 3-mo-old WT and SORLA TG mice were subjected to immunoblotting, and pY602/EphA4 ratios were plotted in B. Graph represents mean ± SE from WT, n = 12, and SORLA TG, n = 12 animals (*, P < 0.04; Student’s t test). (C–E) SORLA suppresses Aβ-mediated EphA4 activation. Aβ 1–42 oligomers (C) were applied to WT or SORLA TG cortical neurons for 2 h, and Eph4 immunoprecipitates (D) were evaluated for EphA4 activation. (E) Relative fold pY602/EphA4 ratios were evaluated for WT and SORLA TG (TG) neurons (graphs depict mean ± SE from three replicates from two independent experiments; *, P < 0.04; Student’s t test). (F and G) SORLA suppresses spatial memory defects associated with hippocampal Aβ injection. WT and SORLA TG mice ( n = 12, each group; n = 48 total, two independent assay runs) were stereotactically injected with PBS or Aβ into the hippocampus and subjected to 5 d of navigational training to find a hidden platform. (F) Escape latency decreased for all groups except WT Aβ-injected animals (red). Graph represents mean ± SE (*, P < 0.03; **, P < 0.008; two-way ANOVA). (G) After training, a probe test was performed to determine whether animals could accurately recall and return to the platform area; the number of entries was automatically recorded for the experimental groups. Significance was determined using one-way ANOVA (mean ± SE; *, P < 0.05). (H and I) SORLA attenuates Aβ-mediated EphA4 activation. Hippocampal tissue from WT (H) and SORLA TG (I) mice injected with PBS or Aβ were subjected to biochemical fractionation after behavioral analysis, and EphA4 immunoprecipitates from membranes/total synaptosomes were immunoblotted for activated EphA4 (pY602) and total EphA4. pY602/EphA4 ratios were normalized to PBS injected samples (set to 1.0). Graphs represent mean ± SE; *, P < 0.05; Student’s t test.$

Journal: The Journal of Experimental Medicine

Article Title: SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration

doi: 10.1084/jem.20171413

Figure Lengend Snippet: SORLA suppresses Aβ-mediated EphA4 activation and attenuates cognitive and synaptotoxic deficits associated with oligomeric Aβ injection in SORLA TG mice. (A and B) SORLA TG mice show a slight reduction in EphA4 activation at steady state. (A) EphA4 immunoprecipitates from crude synaptosome fractions in 3-mo-old WT and SORLA TG mice were subjected to immunoblotting, and pY602/EphA4 ratios were plotted in B. Graph represents mean ± SE from WT, n = 12, and SORLA TG, n = 12 animals (*, P < 0.04; Student’s t test). (C–E) SORLA suppresses Aβ-mediated EphA4 activation. Aβ 1–42 oligomers (C) were applied to WT or SORLA TG cortical neurons for 2 h, and Eph4 immunoprecipitates (D) were evaluated for EphA4 activation. (E) Relative fold pY602/EphA4 ratios were evaluated for WT and SORLA TG (TG) neurons (graphs depict mean ± SE from three replicates from two independent experiments; *, P < 0.04; Student’s t test). (F and G) SORLA suppresses spatial memory defects associated with hippocampal Aβ injection. WT and SORLA TG mice ( n = 12, each group; n = 48 total, two independent assay runs) were stereotactically injected with PBS or Aβ into the hippocampus and subjected to 5 d of navigational training to find a hidden platform. (F) Escape latency decreased for all groups except WT Aβ-injected animals (red). Graph represents mean ± SE (*, P < 0.03; **, P < 0.008; two-way ANOVA). (G) After training, a probe test was performed to determine whether animals could accurately recall and return to the platform area; the number of entries was automatically recorded for the experimental groups. Significance was determined using one-way ANOVA (mean ± SE; *, P < 0.05). (H and I) SORLA attenuates Aβ-mediated EphA4 activation. Hippocampal tissue from WT (H) and SORLA TG (I) mice injected with PBS or Aβ were subjected to biochemical fractionation after behavioral analysis, and EphA4 immunoprecipitates from membranes/total synaptosomes were immunoblotted for activated EphA4 (pY602) and total EphA4. pY602/EphA4 ratios were normalized to PBS injected samples (set to 1.0). Graphs represent mean ± SE; *, P < 0.05; Student’s t test.

Techniques: Activation Assay, Injection, Western Blot, Fractionation

EphA4 redistribution to PSD clusters and LTP impairment is attenuated in SORLA TG mice. (A and B) Hippocampal Aβ injection induces EphA4 redistribution to PSD95 puncta. WT and SORLA TG mice were injected with PBS or Aβ and subjected to immunohistological staining for Aβ (brown) using MOAB-2 antibody (A) or costaining for EphA4 (red) and PSD95 (green; B). DAPI (blue) insets in B depict the dentate gyrus region imaged. Bars: (A) 300 µm; (B) 100 µm. Boxes in A and B are magnified in adjacent panels. EphA4/PSD95 co-staining puncta (yellow) are marked by yellow circles in magified panels in B. (C) Graph indicates percentage of red/green overlapping puncta scored for five 100-µm-square regions from hippocampal sections (mean ± SE; **, P < 0.001; Student’s t test). (D and E) SORLA overexpression restores Aβ-induced LTP impairment. Mean fEPSP slopes normalized over baseline values are shown for WT and SORLA TG acute slices under steady-state conditions with or without 500 nM Aβ as indicated. Baseline recordings were taken 20 min before LTP induction (0 time point), and 60 min after LTP induction. Graph represents mean ± SE; *, P < 0.05. (E) Representative fEPSP recordings obtained before (black) and after (gray) high-frequency stimulation. (F) Cumulative fEPSP slopes between 50 and 60 min after LTP induction (mean ± SE, ≥5 slices per mouse/three mice per genotype/treatment category). Statistical values were calculated using two-way ANOVA; *, P < 0.05.

Journal: The Journal of Experimental Medicine

Article Title: SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration

doi: 10.1084/jem.20171413

Figure Lengend Snippet: EphA4 redistribution to PSD clusters and LTP impairment is attenuated in SORLA TG mice. (A and B) Hippocampal Aβ injection induces EphA4 redistribution to PSD95 puncta. WT and SORLA TG mice were injected with PBS or Aβ and subjected to immunohistological staining for Aβ (brown) using MOAB-2 antibody (A) or costaining for EphA4 (red) and PSD95 (green; B). DAPI (blue) insets in B depict the dentate gyrus region imaged. Bars: (A) 300 µm; (B) 100 µm. Boxes in A and B are magnified in adjacent panels. EphA4/PSD95 co-staining puncta (yellow) are marked by yellow circles in magified panels in B. (C) Graph indicates percentage of red/green overlapping puncta scored for five 100-µm-square regions from hippocampal sections (mean ± SE; **, P < 0.001; Student’s t test). (D and E) SORLA overexpression restores Aβ-induced LTP impairment. Mean fEPSP slopes normalized over baseline values are shown for WT and SORLA TG acute slices under steady-state conditions with or without 500 nM Aβ as indicated. Baseline recordings were taken 20 min before LTP induction (0 time point), and 60 min after LTP induction. Graph represents mean ± SE; *, P < 0.05. (E) Representative fEPSP recordings obtained before (black) and after (gray) high-frequency stimulation. (F) Cumulative fEPSP slopes between 50 and 60 min after LTP induction (mean ± SE, ≥5 slices per mouse/three mice per genotype/treatment category). Statistical values were calculated using two-way ANOVA; *, P < 0.05.

Techniques: Injection, Staining, Over Expression

$EphA4 activation is observed in human AD and correlates with decreased EphA4/SORLA interaction. (A) Total lysates were generated from a representative control and AD cohort and immunoblotted with the indicated antibodies. (B and C) Elevated EphA4 activity is observed in AD. (B) EphA4 was immunoprecipitated from total synaptotosome fractions generated from human frontal cortex and immunoblotted for activated EphA4, pY602, or SORLA as indicated. (C) Activated EphA4 (pY602/EphA4 ratios) as determined in B were plotted for control ( n = 23) and AD ( n = 30) patient cases. Graph represents mean ± SE (**, P < 0.02; Student’s t test). (D) Enhanced SORLA/EphA4 interaction correlates with attenuated EphA4 activation. SORLA/EphA4 and pY602/EphA4 ratios were individually plotted for control (black) and AD (red) patients. R 2 (goodness of fit) values are shown for control (black) and AD (red) data groups; the p-value (significant deviance of the slope from 0 by linear regression analysis) for the AD group was found to be significant.$

Journal: The Journal of Experimental Medicine

Article Title: SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration

doi: 10.1084/jem.20171413

Figure Lengend Snippet: EphA4 activation is observed in human AD and correlates with decreased EphA4/SORLA interaction. (A) Total lysates were generated from a representative control and AD cohort and immunoblotted with the indicated antibodies. (B and C) Elevated EphA4 activity is observed in AD. (B) EphA4 was immunoprecipitated from total synaptotosome fractions generated from human frontal cortex and immunoblotted for activated EphA4, pY602, or SORLA as indicated. (C) Activated EphA4 (pY602/EphA4 ratios) as determined in B were plotted for control ( n = 23) and AD ( n = 30) patient cases. Graph represents mean ± SE (**, P < 0.02; Student’s t test). (D) Enhanced SORLA/EphA4 interaction correlates with attenuated EphA4 activation. SORLA/EphA4 and pY602/EphA4 ratios were individually plotted for control (black) and AD (red) patients. R 2 (goodness of fit) values are shown for control (black) and AD (red) data groups; the p-value (significant deviance of the slope from 0 by linear regression analysis) for the AD group was found to be significant.

Techniques: Activation Assay, Generated, Control, Activity Assay, Immunoprecipitation

Review

Structured Review

Images

Similar Products

Image Search Results